Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Posts Lighter Q2 Revenues Amid Fallen R&D Costs, Narrowed Loss

NEW YORK, July 31 - Caliper Technologies today reported a falloff in total revenue amid decreased R&D spending and a narrowed net loss.

 

Total revenues for the period ended June 30 fell to $5.9 million from $7.2 million year over year. From that, product revenue fell to $3.4 million from $4.5 million in the second quarter of last year. Caliper attributed the decline to a decrease in product sales to Amphora, though it was offset by increases in Caliper's drug-discovery products sales to "unrelated customers" and sales under Caliper's collaboration with Agilent Technologies.

 

Second-quarter R&D spending fell to $8.8 million from $11.5 million in the year-ago period.

 

Net loss in the quarter decreased to $9.5 million, or $.39 per share, from $11.4 million, or $.47 per share, in the second quarter of 2002. Caliper said contributing to the net loss was a restructuring charge of $322,000 in the second quarter that followed a round of layoffs.

 

Caliper said it had around $55 million in cash and cash equivalents.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.